Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 2
Etanercept in the treatment of plaque psoriasis
Published 19 May 2009 Volume 2009:2 Pages 77—84
DOI https://doi.org/10.2147/CCID.S3412
Review by Single anonymous peer review
Peer reviewer comments 3
Thao U Nguyen, John Koo
Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, California, USA
Abstract: Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a dose of 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly thereafter. Clinical studies have shown excellent efficacy, favorable benefit to side-effects ratio, and safe long-term usage. Extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoid arthritis and psoriatic arthritis and is the first of the tumor necrosis factor antagonists to gain approval in psoriasis.
Keywords: etanercept, plaque psoriasis, tumor necrosis factor antagonist
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.